All In Biotech

Drug Trial Radar · NCT07225946

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

800

Planned (sponsor's estimate)

Start

Dec 19, 2025

Primary completion

Nov 19, 2027

Study completion Jun 7, 2030

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Conditions

  • Prostatic Neoplasms, Castration-Resistant

Interventions

  • PasritamigDrug

    Pasritamig will be administered.

  • DocetaxelDrug

    Docetaxel will be administered.

  • Prednisone/PrednisoloneDrug

    Prednisone/Prednisolone will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 1 years 10 months

Locations

165 sites in 17 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Trials

    Chandler, Arizona · Recruiting

  • Arkansas Urology

    Little Rock, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • MemorialCare Orange Coast Medical Center

    Fountain Valley, California · Recruiting

  • University Of California San Diego

    La Jolla, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente Southern California

    Riverside, California · Recruiting

  • Sharp Center for Research

    San Diego, California · Recruiting

  • Providence Saint John s Health Center

    Santa Monica, California · Recruiting

  • Rocky Mountain Cancer Centers

    Aurora, Colorado · Recruiting

  • AdventHealth Porter Oncology Research

    Denver, Colorado · Recruiting

  • Vail Health Shaw Cancer Center

    Edwards, Colorado · Recruiting

  • Grand Valley Oncology

    Grand Junction, Colorado · Recruiting

  • Colorado Clinical Research

    Lakewood, Colorado · Recruiting

  • AdventHealth Orlando

    Orlando, Florida · Recruiting

  • Memorial Cancer Institute

    Pembroke Pines, Florida · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Winship Cancer Institute Emory University

    Atlanta, Georgia · Recruiting

  • Duly Health and Care

    Lisle, Illinois · Recruiting

  • Cancer Center of Kansas Heritage Plaza Medical Building

    Wichita, Kansas · Recruiting

  • St Elizabeth Healthcare

    Edgewood, Kentucky · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • East Jefferson General Hospital

    Metairie, Louisiana · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Medical Institutions

    Baltimore, Maryland · Recruiting

  • Center for Cancer and Blood Disorders

    Bethesda, Maryland · Recruiting

  • Chesapeake Urology Research Associates

    Towson, Maryland · Recruiting

  • Massachusetts General

    Boston, Massachusetts · Recruiting

  • Profound Research LLC at Cancer and Leukemia Center

    Sterling Heights, Michigan · Recruiting

  • HealthPartners Frauenshuh Cancer Center CRC West

    Saint Louis Park, Minnesota · Recruiting

  • HealthPartners Cancer Center at Regions Hospital CRC East

    Saint Paul, Minnesota · Recruiting

  • University of Mississippi Medical Center

    Jackson, Mississippi · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • NHO Revive Research Institute, LLC

    Lincoln, Nebraska · Recruiting

  • Cooper Health System MD Anderson Cancer Center at Cooper

    Camden, New Jersey · Recruiting

  • Astera Cancer Care

    East Brunswick, New Jersey · Recruiting

Showing 40 of 165 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.